Compare Biocon with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs JUBILANT LIFE SCIENCES - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON JUBILANT LIFE SCIENCES BIOCON /
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 31.6 15.8 200.6% View Chart
P/BV x 3.8 2.9 128.0% View Chart
Dividend Yield % 0.3 0.5 51.6%  

Financials

 BIOCON    JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    BIOCON
Mar-19
JUBILANT LIFE SCIENCES
Mar-19
BIOCON /
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs707898 78.8%   
Low Rs554618 89.7%   
Sales per share (Unadj.) Rs91.9572.0 16.1%  
Earnings per share (Unadj.) Rs16.736.2 46.1%  
Cash flow per share (Unadj.) Rs24.259.5 40.6%  
Dividends per share (Unadj.) Rs1.004.50 22.2%  
Dividend yield (eoy) %0.20.6 26.7%  
Book value per share (Unadj.) Rs101.6301.9 33.7%  
Shares outstanding (eoy) m600.00159.28 376.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.91.3 517.9%   
Avg P/E ratio x37.720.9 180.4%  
P/CF ratio (eoy) x26.112.7 204.9%  
Price / Book Value ratio x6.22.5 247.2%  
Dividend payout %6.012.4 48.2%   
Avg Mkt Cap Rs m378,330120,694 313.5%   
No. of employees `0006.12.4 256.5%   
Total wages/salary Rs m11,65319,260 60.5%   
Avg. sales/employee Rs Th8,994.338,120.6 23.6%   
Avg. wages/employee Rs Th1,900.78,058.4 23.6%   
Avg. net profit/employee Rs Th1,635.32,414.3 67.7%   
INCOME DATA
Net Sales Rs m55,14491,108 60.5%  
Other income Rs m1,444357 404.0%   
Total revenues Rs m56,58891,466 61.9%   
Gross profit Rs m15,88317,390 91.3%  
Depreciation Rs m4,4783,709 120.7%   
Interest Rs m7092,198 32.3%   
Profit before tax Rs m12,14011,840 102.5%   
Minority Interest Rs m90-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,802 0.0%   
Tax Rs m2,1233,268 65.0%   
Profit after tax Rs m10,0265,770 173.8%  
Gross profit margin %28.819.1 150.9%  
Effective tax rate %17.527.6 63.4%   
Net profit margin %18.26.3 287.1%  
BALANCE SHEET DATA
Current assets Rs m48,22845,848 105.2%   
Current liabilities Rs m30,37620,897 145.4%   
Net working cap to sales %32.427.4 118.2%  
Current ratio x1.62.2 72.4%  
Inventory Days Days6857 120.2%  
Debtors Days Days8651 167.8%  
Net fixed assets Rs m64,13065,498 97.9%   
Share capital Rs m3,000159 1,883.2%   
"Free" reserves Rs m57,98047,930 121.0%   
Net worth Rs m60,98048,089 126.8%   
Long term debt Rs m15,76642,429 37.2%   
Total assets Rs m121,924114,685 106.3%  
Interest coverage x18.16.4 283.8%   
Debt to equity ratio x0.30.9 29.3%  
Sales to assets ratio x0.50.8 56.9%   
Return on assets %8.86.9 126.7%  
Return on equity %16.412.0 137.0%  
Return on capital %16.812.4 135.0%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,50612,422 124.8%   
Fx outflow Rs m10,39917,227 60.4%   
Net fx Rs m5,107-4,805 -106.3%   
CASH FLOW
From Operations Rs m11,54611,215 103.0%  
From Investments Rs m-7,138-10,118 70.5%  
From Financial Activity Rs m-2,4176,574 -36.8%  
Net Cashflow Rs m2,1037,612 27.6%  

Share Holding

Indian Promoters % 40.4 45.6 88.6%  
Foreign collaborators % 20.6 3.5 588.6%  
Indian inst/Mut Fund % 8.4 8.7 96.6%  
FIIs % 10.7 21.2 50.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 21.1 94.3%  
Shareholders   109,995 23,815 461.9%  
Pledged promoter(s) holding % 0.0 15.9 0.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   AUROBINDO PHARMA  ORCHID PHARMA  SANOFI INDIA  FULFORD INDIA  SHASUN PHARMA  

Compare BIOCON With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 531 Points; Reliance Industries & IndusInd Bank Fall 5%(Closing)

Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.

Related Views on News

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

JUBILANT LIFE SCIENCES Share Price Down by 5%; BSE 500 Index Down 1.0% (Market Updates)

Jan 25, 2021 | Updated on Jan 25, 2021

JUBILANT LIFE SCIENCES share price is trading down by 5% and its current market price is Rs 956. The BSE 500 is down by 1.0%. The top gainers in the BSE 500 Index are GATEWAY DISTRIPARKS (up 10.9%) and NCC (up 6.4%). The top losers are JUBILANT LIFE SCIENCES (down 5.5%) and INFO EDGE (down 6.9%).

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY20); Net Profit Up 358.8% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 358.8% YoY). Sales on the other hand came in at Rs 24 bn (up 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY20); Net Profit Down 24.0% (Quarterly Result Update)

Feb 1, 2020 | Updated on Feb 1, 2020

For the quarter ended December 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 24.0% YoY). Sales on the other hand came in at Rs 23 bn (down 2.6% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

Buzzing Sectors Before Budget 2021(Fast Profits Daily)

Jan 12, 2021

The budget is just a few weeks away. Which stocks can you expect to move? Find out in this video.

Here's Why Smallcaps Could Be Your Best Investment in 2021(Profit Hunter)

Jan 12, 2021

Select smallcaps hold a great potential to become the multibaggers of tomorrow. Here's how you could get in early into these stocks.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jan 25, 2021 (Close)

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS